Moderna is trading roughly flat today as the stock consolidates following a period of high volatility.
The shares experienced significant downward pressure earlier this week after Citigroup downgraded the stock to a sell rating, citing concerns that a 500% rally this year had pushed the valuation ahead of the company's pipeline potential. While the stock recently hit a 52-week high of $208.90, it continues to face headw